Exemestane with varian suppression in premenopausal Breast Cancer

New England Journal of Medicine

Volumn 371, Issue 14, 2014, Pages 1358-1359

  Pagani, Olivia ^a   Regan, Meredith M ^b   Francis, Prudence A ^c  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b International Breast Cancer Study Group Statistical Center   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; TRIPTORELIN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; EARLY CANCER; FEMALE; FOLLOW UP; HEALTH CARE COST; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; LETTER; OVARIAN SUPPRESSION; OVERALL SURVIVAL; PREMENOPAUSE; RECURRENCE RISK; RISK REDUCTION; TIME TO TREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; BREAST TUMOR; NOTE;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN; TRIPTORELIN PAMOATE;

EID: 84907722176     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEjMci1409366     Document Type: Letter

References (5)

1. Demicheli R, Ardoino I, Boracchi P, et al. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery: ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 2010;10:656-64.
2. Bellet M, Gray KP, Francis PA, et al. Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy. J Clin Oncol 2014;32:Suppl:26s. abstract.
3. Anderson BO. The Breast Health Global Initiative: why it matters to all of us. Oncology (Williston Park) 2010;24:1230-4.
4. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28. [Erratum, J Natl Cancer Inst 2011;103:699.J
5. Schnipper LE. ASCO Annual Meeting 2014: highlights of the day session (http://meetinglibrary.asco.org/content/98913?media =vm).